Genmab — Maj 2020
-
De kloge antyder nok...det er indregnet!;-)
-
Ærgeligt med gode nyheder i et så surt marked!
-
Go´ pointe JKY
-
Halozyme price target raised to $39 from $35 at Cantor Fitzgerald Cantor Fitzgerald analyst Charles Duncan raised the firm's price target on Halozyme (HALO) to $39 from $35 and keeps an Overweight rating on the shares after the company announced that the ENHANZE-based DARZALEX subcutaneous formulation, now called DARZALEX FASPRO, which is licensed to Janssen (JNJ), was approved by the FDA. Duncan tells investors in a research note that because the breadth of the approved label exceeds even his
-
Jan varslede i forbindelse med interview omkring GF. nærmere en nedjustering af dara salg pga corona
-
Så jeg serr ikke en opjustering komme uden der er lavet en ny liccensdeal med upfront betaling
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind